NCT06402877

Brief Summary

: The aim of this study is; detection of Adseverin,1-alpha Defensin,sRANKL(soluble RANKL) levels in saliva samples of periodontally healthy, gingivitis and periodontitis patients and the possible correlation between these values and clinical parameters of periodontal diseases. Materials and methods: Samples of saliva were obtained from 60 systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20). Full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were also recorded. Enzyme-linked immunosorbent assay (ELISA) was used to determine Adseverin,1-alpha Defensin,sRANKL(soluble RANKL) levels in the biological samples.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 26, 2024

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

May 3, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 7, 2024

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 25, 2025

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 24, 2025

Completed
Last Updated

December 9, 2025

Status Verified

May 1, 2024

Enrollment Period

10 months

First QC Date

May 3, 2024

Last Update Submit

December 2, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • The total amount of Adseverin in saliva

    The total amount of Adseverin in saliva

    24 hours after taking the clinical measurements at the first visit]

  • The total amount of 1-Alpha Defensin in saliva

    The total amount of 1-Alpha Defensin in saliva

    24 hours after taking the clinical measurements at the first visit

  • The total amount of sRANKL in saliva

    The total amount of soluble RANKL in saliva

    24 hours after taking the clinical measurements at the first visit

Study Arms (3)

Healthy Periodontium

EXPERIMENTAL

Full-mouth clinical periodontal measurements recorded and saliva obtain

Diagnostic Test: Saliva obtaining

Periodontitis

EXPERIMENTAL

Full-mouth clinical periodontal measurements recorded and saliva obtained.

Diagnostic Test: Saliva obtaining

Gingivitis

EXPERIMENTAL

Full-mouth clinical periodontal measurements recorded and saliva obtained.

Diagnostic Test: Saliva obtaining

Interventions

Saliva obtainingDIAGNOSTIC_TEST

The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.

GingivitisHealthy PeriodontiumPeriodontitis

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Systemically healthy (The determination of healthy volunteers will be based on the statements of the patients in the anamnesis. No additional examinations will be made.) At least twenty permanent teeth in the mouth Non-smoker No medication for continuous use Those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months.
  • Not in pregnancy or lactation period. For the periodontitis group that has not received periodontal treatment in the last 6 months For the periodontitis group; According to the evaluation made in 6 regions of each tooth, individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss For the gingivitis group; According to the evaluation made in 6 regions of each tooth, individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss For healthy group; According to the evaluation made in 6 regions of each tooth,individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study.

You may not qualify if:

  • Any oral or systemic disease Regularly using a systemic medication During pregnancy or lactation Received periodontal treatment within the last 6 months. Those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months Smokers are not included in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Izmir Katip Çelebi University Department of Periodontology

Izmir, Çiğli, 35640, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Periodontal Diseases

Condition Hierarchy (Ancestors)

Mouth DiseasesStomatognathic Diseases

Study Officials

  • Ayşe Efe

    Izmir Katip Çelebi University Department of Periodontology İzmir, Çiğli, Turkey, 35640

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Model Details: According to full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL),bleeding on probing (BOP), gingival index (GI) and plaque index (PI) samples of saliva were obtained from 60 systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20).
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Assistant at Periodontology

Study Record Dates

First Submitted

May 3, 2024

First Posted

May 7, 2024

Study Start

April 26, 2024

Primary Completion

February 25, 2025

Study Completion

November 24, 2025

Last Updated

December 9, 2025

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL, SAP, ICF

Locations